Latest Breaking News On - Insider transactions at olema pharmaceuticals - Page 1 : comparemela.com

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 8%

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 8%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Cyrus harmonGroup plcSecurities exchange commissionPerceptive advisorsHedge funds weigh in on olema pharmaceuticalsNews ratings for olema pharmaceuticals dailyVanguard group incOlema pharmaceuticals company profileInsider transactions at olema pharmaceuticalsBarclays plcOlema pharmaceuticals incOlema pharmaceuticals stock downOlema pharmaceuticalsGet free reportOne financialPharmaceuticals stock down

Olema Pharmaceuticals, Inc (NASDAQ:OLMA) Receives $20 25 Consensus Target Price from Analysts

Olema Pharmaceuticals, Inc (NASDAQ:OLMA) Receives $20 25 Consensus Target Price from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Cyrus harmonAnalyst recommendations for olema pharmaceuticalsNews ratings for olema pharmaceuticals dailyCredit suisse groupJpmorgan chase coRoyal bankCitigroup incBalyasny asset managementOlema pharmaceuticals incVirtu financialOlema pharmaceuticals trading downInsider transactions at olema pharmaceuticalsOlema pharmaceuticalsGet free reportOne financialSuisse group

JPMorgan Chase & Co Boosts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $16 00

JPMorgan Chase & Co Boosts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $16 00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCyrus harmonPrelude capital managementCredit suisse groupInsider transactions at olema pharmaceuticalsSectoral asset management incOlema pharmaceuticals incOlema pharmaceuticals trading downAnalyst recommendations for olema pharmaceuticalsNews ratings for olema pharmaceuticals dailyOlema pharmaceuticalsCapital partnersYork life investment managementInstitutional investors weigh in on olema pharmaceuticalsOlema pharmaceuticals company profile

Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at Oppenheimer

Equities research analysts at Oppenheimer started coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) in a research note issued to investors on Thursday, FlyOnTheWall reports. The brokerage set an “outperform” rating on the stock. Several other equities research analysts have also commented on OLMA. Lifesci Capital reiterated an “outperform” rating on shares […]

Cyrus harmonOlema pharmaceuticals company profileOlema pharmaceuticals incNews ratings for olema pharmaceuticals dailyOlema pharmaceuticalsInsider transactions at olema pharmaceuticalsOlema pharmaceuticals price performanceRenaissance technologiesAcadian asset managementInstitutional trading of olema pharmaceuticalsPrelude capital managementBlackrock incJpmorgan chase coGet free reportOne financialDirector cyrus harmon